MedTrace Logo

Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

NCT01514149 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2017-07-19

Study results available
· View outcomes & findings →

Summary

DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

CJC-1134-PC Injection

CJC-1134-PC administered weekly by subcutaneous injection

DRUG

Weekly placebo for CJC-1134-PC Injection

Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection

Sponsors & Collaborators

  • ConjuChem

    lead INDUSTRY

Principal Investigators

  • Patrick Soon-Shiong, MD · Chief Executive Officer

  • Robert Henry, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-05-31
Completion
2013-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01514149 on ClinicalTrials.gov